Surface epithelial-stromal tumor
|Surface epithelial-stromal tumor|
|Other names: Surface epithelial tumors|
|High magnification micrograph of a Brenner tumor, a type of surface epithelial-stromal tumor. H&E stain.|
|Types||Serous, mucinous, endometrioid, clear cells, transitional cell, epithelial-stromal|
|Risk factors||Not having children, high fat diet, family history, late menopause|
|Diagnostic method||Suspected based on medical imaging, confirmed by microscopic examination.|
|Prevention||Tubal ligation, birth control pills|
|Frequency||66% of ovarian tumors, 90% of ovarian cancers|
Surface epithelial-stromal tumors are a class of ovarian tumors. They account for about 66% of ovarian tumors and 90% of ovarian cancers. Symptoms may include a pelvic mass. Complications may include peritoneal carcinomatosis.
Types include serous tumors, mucinous tumors, endometrioid tumors, clear cell tumors, transitional cell tumors, and epithelial-stromal such as carcinosarcoma. Serous tumors make up about 30%, mucinous about 13%, and endometroid about 3% of ovarian tumors. They can be further classified as benign (60%), borderline (5%), or malignant (35%). Some malignant versions are known as ovarian adenocarcinomas.
Risk factors include not having children, high fat diet, family history, and late menopause. A tubal ligation and the use of birth control pills decreases the risk. They are believed to start from the ovarian surface epithelium, endometrium or fallopian tubes. Diagnosis is often suspected based on medical imaging and confirmed by microscopic examination.
Epithelial-stromal tumors are classified on the basis of the epithelial cell type, the relative amounts of epithelium and stroma, the presence of papillary processes, and the location of the epithelial elements. Microscopic pathological features determine whether a surface epithelial-stromal tumor is benign, a borderline tumor, or malignant (evidence of malignancy and stromal invasion). Borderline tumors are of uncertain malignant potential.
- These tumors vary in size from small and nearly imperceptible to large, filling the abdominal cavity.
- Benign, borderline, and malignant types of serous tumors account for about 30% of all ovarian tumors.
- 75% are benign or of borderline malignancy, and 25% are malignant
- The malignant form of this tumor, serous cystadenocarcinoma, accounts for approximately 40% of all carcinomas of the ovary and are the most common malignant ovarian tumors.
- Benign and borderline tumors are most common between the ages of 20 and 50 years.
- Malignant serous tumors occur later in life on average, although somewhat earlier in familial cases.
- 20% of benign, 30% of borderline, and 66% of malignant tumors are bilateral (affect both ovaries).
Components can include:
- cystic areas
- cystic and fibrous areas
- predominantly fibrous areas
The chance of malignancy of the tumor increases with the amount of solid areas present, including both papillary structures and any necrotic tissue present.
- lined by tall, columnar, ciliated epithelial cells
- filled with clear serous fluid
- the term serous which originated as a description of the cyst fluid has come to be describe the particular type of epithelial cell seen in these tumors
- may involve the surface of the ovary
- the division between benign, borderline, and malignant is ascertained by assessing:
- cellular atypia (whether or not individual cells look abnormal)
- invasion of surrounding ovarian stroma (whether or not cells are infiltrating surrounding tissue)
- borderline tumors may have cellular atypia but do NOT have evidence of invasion
- the presence of psammoma bodies are a characteristic microscopic finding of cystadenocarcinomas
The prognosis of a serous tumor, like most neoplasms, depends on
- degree of differentiation
- this is how closely the tumor cells resemble benign cells
- a well-differentiated tumor closely resembles benign tumors
- a poorly differentiated tumor may not resemble the cell type of origin at all
- a moderately differentiated tumor usually resembles the cell type of origin, but appears frankly malignant
- extension of tumor to other structures
- in particular with serous malignancies, the presence of malignant spread to the peritoneum is important with regard to prognosis.
While the 5-year survival rates of borderline tumors are excellent, this should not be seen as evidence of cure, as recurrences can occur many years later.
- Closely resemble their serous counterparts but unlikely to be bilateral
- Somewhat less common, accounting for about 25% of all ovarian neoplasms
- In some cases mucinous tumors are characterized by more cysts of variable size and a rarity of surface involvement as compared to serous tumors
- Also in comparison to serous tumors, mucinous tumors are less frequently bilateral, approximately 5% of primary mucinous tumors are bilateral.
- May form very large cystic masses, with recorded weights exceeding 25 kg
Mucinous tumors are characterized by a lining of tall columnar epithelial cells with apical mucin and the absence of cilia, similar in appearance with benign cervical or intestinal epithelia. The appearance can look similar to colonic or ovarian cancer, but typically originates from the appendix (see mucinous adenocarcinoma with clinical condition Pseudomyxoma peritonei). Clear stromal invasion is used to differentiate borderline tumors from malignant tumors.
10-year survival rates for borderline tumors contained within the ovary, malignant tumors without invasion, and invasive malignant tumors are greater than 95%, 90%, and 66%, respectively. One rare but noteworthy condition associated with mucinous ovarian neoplasms is pseudomyxoma peritonei. As primary ovarian mucinous tumors are usually unilateral (in one ovary), the presentation of bilateral mucinous tumors requires exclusion of a non-ovarian origin, usually the appendix.
Endometrioid tumors account for approximately 20% of all ovarian cancers and are mostly malignant (endometroid carcinomas). They are made of tubular glands bearing a close resemblance to benign or malignant endometrium. 15-30% of endometrioid carcinomas occur in individuals with carcinoma of the endometrium, and these patients have a better prognosis. They appear similar to other surface epithelial-stromal tumors, with solid and cystic areas. 40% of these tumors are bilateral, when bilateral, metastases is often present.
- Glands bearing a strong resemblance to endometrial-type glands
- Benign tumors have mature-appearing glands in a fibrous stroma
- Borderline tumors have a complex branching pattern without stromal invasion
- Carcinomas (malignant tumors) have invasive glands with crowded, atypical cells, frequent mitoses. With poorer differentiation, the tumor becomes more solid.
Prognosis again is dependent on the spread of the tumor, as well as how differentiated the tumor appears. The overall prognosis is somewhat worse than for serous or mucinous tumors, and the 5-year survival rate for patients with tumors confined to the ovary is approximately 75%.
Clear cell tumors
Clear cell tumors are characterized by large epithelial cells with abundant clear cytoplasm and may be seen in association with endometriosis or endometrioid carcinoma of the ovary, bearing a resemblance to clear cell carcinoma of the endometrium. They may be predominantly solid or cystic. If solid, the clear cells tend to be arranged in sheets or tubules. In the cystic variety, the neoplastic cells make up the cyst lining.
These tumors tend to be aggressive, the five year survival rate for tumors confined to the ovaries is approximately 65%. If the tumor has spread beyond the ovary at diagnosis, the prognosis is poor
Brenner tumors are uncommon surface-epithelial stromal cell tumors in which the epithelial cell (which defines these tumors) is a transitional cell. These are similar in appearance to bladder epithelia. The tumors may be very small to very large, and may be solid or cystic. Histologically, the tumor consists of nests of the aforementioned transitional cells within surrounding tissue that resembles normal ovary. Brenner tumors may be benign or malignant, depending on whether the tumor cells invade the surrounding tissue.
Small cell tumors
The World Health Organisation (WHO) recognises SCCO as two distinct entities: Small Cell Ovarian Cancer of Hypercalcemic Type (SCCOHT) Archived 2019-02-14 at the Wayback Machine and Small Cell Ovarian Cancer of Pulmonary Type (SCCOPT).
Small cell tumours are rare and aggressive, they contribute to less than 2% of all gynaecologic malignancies. The average age of diagnosis is 24 years old, and the majority of patients also present with hypercalcemia (62%). It typically present with a unilateral large tumor. Most women die within a year of diagnosis.
For more general information, see ovarian cancer.
Research suggests that in the first line treatment of Endometrial Ovarian Cancer (EOC), Pegylated Liposomal Doxorubicin paired with Carboplatin is a satisfactory alternative to Paclitaxel with Carboplatin. In people with platinum-sensitive relapsed EOC, research has found that Pegylated Liposomal Doxorubicin with Carboplatin is a better treatment than Paclitaxel with Carboplatin.
For advanced cancer of this histology, the US National Cancer Institute recommends a method of chemotherapy that combines intravenous (IV) and intraperitoneal (IP) administration. Preferred chemotherapeutic agents include a platinum drug with a taxane.
Effect on fertility
Fertility subsequent to treatment of surface epithelial-stromal tumors depends mainly on histology and initial staging to separate it into early borderline (or more benign) versus advanced stages of borderline (or more malignant). Conservative management (without bilateral oophorectomy) of early stage borderline tumors have been estimated to result in chance of over 50% of spontaneous pregnancy with a low risk of lethal recurrence of the tumor (0.5%). On the other hand, in cases of conservative treatment in advanced stage borderline tumors, spontaneous pregnancy rates have been estimated to be 35% and the risk of lethal recurrence 2%.
- Saba, Luca; Acharya, U. Rajendra; Guerriero, Stefano; Suri, Jasjit S. (2014). Ovarian Neoplasm Imaging. Springer Science & Business Media. p. 243. ISBN 978-1-4614-8633-6. Archived from the original on 2021-07-10. Retrieved 2021-02-22.
- "WHO classification". www.pathologyoutlines.com. Archived from the original on 17 January 2021. Retrieved 22 February 2021.
- Nucci, Marisa R.; Oliva, Esther (2009). Gynecologic Pathology: A Volume in the Series: Foundations in Diagnostic Pathology. Elsevier Health Sciences. p. 393. ISBN 978-0-443-06920-8. Archived from the original on 2021-07-10. Retrieved 2021-02-22.
- Sternberg, Stephen S.; Mills, Stacey E.; Carter, Darryl (2004). Sternberg's Diagnostic Surgical Pathology. Lippincott Williams & Wilkins. p. 2544. ISBN 978-0-7817-4051-7. Archived from the original on 2021-07-12. Retrieved 2021-02-22.
- - Vaidya, SA; Kc, S; Sharma, P; Vaidya, S (2014). "Spectrum of ovarian tumors in a referral hospital in Nepal". Journal of Pathology of Nepal. 4 (7): 539–543. doi:10.3126/jpn.v4i7.10295. ISSN 2091-0908.
- Minor adjustment for mature cystic teratomas (0.17 to 2% risk of ovarian cancer): Mandal, Shramana; Badhe, Bhawana A. (2012). "Malignant Transformation in a Mature Teratoma with Metastatic Deposits in the Omentum: A Case Report". Case Reports in Pathology. 2012: 1–3. doi:10.1155/2012/568062. ISSN 2090-6781. PMC 3469088. PMID 23082264.
- Kosary CL (2007). "Chapter 16: Cancers of the Ovary" (PDF). In Baguio RN, Young JL, Keel GE, Eisner MP, Lin YD, Horner MJ (eds.). SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics. SEER Program. Vol. NIH Pub. No. 07-6215. Bethesda, MD: National Cancer Institute. pp. 133–144. Archived from the original on 2013-10-10. Retrieved 2012-07-19.
- Baradwan, Saeed; Alalyani, Haneen; Baradwan, Amira; Baradwan, Afnan; Al-Ghamdi, Maram; Alnemari, Jameel; Al-Jaroudi, Dania (2018). "Bilateral ovarian masses with different histopathology in each ovary". Clinical Case Reports. 6 (5): 784–787. doi:10.1002/ccr3.1466. ISSN 2050-0904. PMC 5930217. PMID 29744056.
- Creative Commons Attribution 4.0 International (CC BY 4.0) license Archived 2017-10-16 at the Wayback Machine
- Cotran, Ramzi S.; Kumar, Vinay; Nelson, Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease (7th ed.). St. Louis, Mo: Elsevier Saunders. ISBN 978-0-7216-0187-8.
- Atlas of Genetics and Cytogenetics in Oncology and Haematology - Ovary: Epithelial tumors Archived 2014-06-26 at the Wayback Machine. Retrieved June 2014. By Lee-Jones, L. Atlas Genet Cytogenet Oncol Haematol. 2004;8(2):115-133.
- Kaphan, Ariel A.; Castro, Cesar M. (2014-01-01). MPH, rcela G. del Carmen MD; FRCPATH, Robert H. Young MD; MD, John O. Schorge; MD, Michael J. Birrer (eds.). Small Cell and Neuroendocrine Cancers of the Ovary. John Wiley & Sons, Ltd. pp. 139–147. doi:10.1002/9781118655344.ch12. ISBN 9781118655344.
- Bakhru A, Liu JR, Lagstein A (2012). "A case of small cell carcinoma of the ovary hypercalcemic variant in a teenager". Gynecologic Oncology Case Reports. 2 (4): 139–42. doi:10.1016/j.gynor.2012.09.001. PMC 3861231. PMID 24371647.
- Lawrie TA, Rabbie R, Thoma C, Morrison J, et al. (The Cochrane Collaboration) (October 2013). Lawrie TA (ed.). "Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer". The Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd (10): CD010482. doi:10.1002/14651858.cd010482.pub2. PMC 6457824. PMID 24142521. Archived from the original on 2021-08-29. Retrieved 2020-03-12.
- Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J (July 2013). "Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer". The Cochrane Database of Systematic Reviews (7): CD006910. doi:10.1002/14651858.cd006910.pub2. PMC 6457816. PMID 23835762.
- "NCI Issues Clinical Announcement for Preferred Method of Treatment for Advanced Ovarian Cancer". National Cancer Institute. January 2006. Archived from the original on 9 January 2009.
- Kolomainen DF, Larkin JM, Badran M, A'Hern RP, King DM, Fisher C, et al. (February 2002). "Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence". Journal of Clinical Oncology. 20 (4): 982–6. doi:10.1200/JCO.2002.20.4.982. PMID 11844820.
- Daraï E, Fauvet R, Uzan C, Gouy S, Duvillard P, Morice P (2012). "Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options". Human Reproduction Update. 19 (2): 151–66. doi:10.1093/humupd/dms047. PMID 23242913.